Abstract
Retrovirus-mediated gene therapy is a particularly attractive approach for glioblastoma multiforme (GBM), given the poor prognosis of this tumour and its localized proliferation in post-mitotic tissue. In this study we assessed, for the first time in humans, the therapeutic potential of a newly designed bicistronic Moloney vector (pLIL-2-TK), combining the expression of a suicide gene (thymidine kinase, tk) with an immunomodulatory gene (human interleukin 2, IL-2). Evidence of transgene activity in the treated tumours is presented.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Oldfield EH et al. Clinical protocol: gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir Hum Gene Ther 1993 4: 39–69
Elshami AA et al. Gap junctions play a role in the ‘bystander effect’ of the herpes simplex virus thymidine kinase/ganciclovir system in vitro Gene Therapy 1996 3: 85–92
Hamel W et al. Herpes simplex virus thymidine kinase/ganciclovir-mediated apoptotic death of bystander cells Cancer Res 1996 56: 2697–2701
Long Z et al. Biosafety monitoring of patients receiving intracerebral injections of murine retroviral vector producer cells Hum Gene Ther 1998 9: 1165–1172
Karnofsky DA, Burchenal JH . The clinical evaluation of chemotherapeutic agents in cancer. In: McLeod CM (ed) . Evaluation of Chemotherapeutic Agents Columbia University Press: New York 1945 191–205
Chilosi M et al. Multimarker immunohistochemical staining of calgranulins, chloroacetate esterase, and S100 for simultaneous demonstration of inflammatory cells on paraffin sections J Histochem Cytochem 1990 38: 1669–1675
Vile RG et al. Generation of an anti-tumour immune response in a non-immunogenic tumour: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoural cytokine expression Int J Cancer 1997 71: 267–274
Pizzato M et al. Production and characterization of a bicistronic Moloney-based retroviral vector expressing human interleukin 2 and herpes simplex virus thymidine kinase for gene therapy of cancer Gene Therapy 1998 5: 1003–1007
Barba D et al. Intratumoral LAK cell and interleukin 2 therapy of human gliomas J Neurosurg 1989 70: 175–182
O’Reilly MS et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth Cell 1997 88: 277–285
Bi WL et al. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSVtk retroviral gene therapy Hum Gene Ther 1993 4: 725–731
Ram Z et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells Nature Med 1997 3: 1354–1361
Tjuvajev J et al. RG-2 glioma growth attenuation and severe brain edema caused by local production of interleukin-2 and interferon-gamma Cancer Res 1995 55: 1902–1910
Freeman SM et al. The ‘bystander effect’: tumor regression when a fraction of the tumor mass is genetically modified Cancer Res 1993 53: 5274–5283
Hamel W, Magnelli L, Chiarugi VP, Isreal MA . Herpes simplex virus thymidine kinase/ganciclovir-mediated apoptotic death of bystander cells Cancer Res 1996 56: 2697–2702
Freeman SM et al. The role of cytokines in mediating the bystander effect using HSV-tk xenogeneic cells Cancer Lett 1995 92: 167–174
Gagandeep S et al. Prodrug-activated gene therapy: involvement of an immunological component in the ‘bystander effect’ Cancer Gene Ther 1996 3: 83–88
Yamamoto S et al. Herpes simplex virus thymidine kinase/ganciclovir-mediated killing of tumor cell induces tumor-specific cytotoxic T cells in mice Cancer Gene Ther 1997 4: 91–96
Meazza R et al. Analysis of IL-2 receptor expression and of the biological effects of IL-2 gene transfection in small-cell lung cancer Br J Cancer 1996 74: 788–795
Riddell SR et al. T-cell mediated rejection of gene-modifiedHIV-specific cytotoxic T lymphocytes in HIV-infected patients Nature Med 1996 2: 216–223
Colombo MP, Forni G . Immunotherapy I: cyclosine gene transfer strategies Cancer Metastasis Rev 1996 15: 317–328
Corrias MV et al. Characterization and tumorigenicity of human neuroblastoma cells transfected with the IL-2 gene Cancer Gene Ther 1998 5: 38–44
Cosset FL et al. High-titer packaging cells producing recombinant retroviruses resistant to human serum J Virol 1995 69: 7430–7436
Ram Z et al. Summary of results and conclusions of the gene therapy of malignant brain tumors: clinical study J Neurosurg 1995 82: 343A
Rho HM et al. Characterization of the reverse transcriptase from a new retrovirus (HTLV) produced by a human cutaneous T-cell lymphoma cell line Virology 1981 112: 355–360
Chomczynski P, Sacchi N . Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction Anal Biochem 1987 162: 156–159
Schaeren-Wiemers N, Gerfin-Moser A . A single protocol to detect transcripts of various types and expression levels in neural tissue and cultured cells: in situ hybridization using digoxigenin-labelled cRNA probes Histochemistry 1993 100: 431–440
Chilosi M et al. p21/WAF1 cyclin-kinase inhibitor expression in non-Hodgkin’s lymphomas: a potential marker of p53 tumor-suppressor gene function Blood 1996 88: 4012–4020
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Palù, G., Cavaggioni, A., Calvi, P. et al. Gene therapy of glioblastoma multiforme via combined expression of suicide and cytokine genes: a pilot study in humans. Gene Ther 6, 330–337 (1999). https://doi.org/10.1038/sj.gt.3300805
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3300805
Keywords
This article is cited by
-
Recent progress in the research of suicide gene therapy for malignant glioma
Neurosurgical Review (2021)
-
Prognostic utility of gene therapy with herpes simplex virus thymidine kinase for patients with high-grade malignant gliomas: a systematic review and meta analysis
Journal of Neuro-Oncology (2014)
-
Progress in gene therapy for neurological disorders
Nature Reviews Neurology (2013)
-
Gene therapy as an adjuvant treatment for malignant gliomas: from bench to bedside
Journal of Neuro-Oncology (2009)
-
Flt3L in Combination With HSV1-TK-mediated Gene Therapy Reverses Brain Tumor–induced Behavioral Deficits
Molecular Therapy (2008)